Table 1.
Baseline demographic and clinical characteristics for all patients.
| RIC group (n = 24) | Sham‐RIC group (n = 25) | |
|---|---|---|
| Age (years) | 59.5 ± 8.5 | 61.3 ± 11.0 |
| Males patients | 20 (83.3%) | 18 (72.0%) |
| Blood pressure (mmHg) | ||
| Systolic pressure | 151.1 ± 20.3 | 154.0 ± 18.7 |
| Diastolic pressure | 92.1 ± 10.5 | 86.1 ± 10.4 |
| Blood glucose (mmol/L) | 8.25 (6.63, 8.88) | 7.70 (6.65, 9.25) |
| OTT (min) | 177.8 ± 44.4 | 192.2 ± 48.7 |
| NIHSS before thrombolysis | 7.0 (6.0, 11.0) | 9.0 (5.5, 11.5) |
| NIHSS before RIC | 6.5 (2.3, 9.8) | 5.0 (4.0, 9.0) |
| Past medical history | ||
| Hypertension | 11 (45.8%) | 16 (64.0%) |
| Diabetes mellitus | 6 (25.0%) | 5 (20.0%) |
| Smoking | 13 (54.2%) | 16 (64.0%) |
| Drinking | 11 (45.8%) | 15 (60.0%) |
| TIA | 0 (0.0%) | 1 (4.0%) |
| Stroke | 11 (45.8%) | 6 (24.0%) |
| CHD | 2 (8.3%) | 2 (8.0%) |
| Current use of antiplatelet agents | 1 (4.2%) | 0 (0.0%) |
| CISS | ||
| LAA | 8 (33.3%) | 9 (36.0%) |
| CS | 1 (4.2%) | 0 (0.0%) |
| PAD | 11 (45.8%) | 11 (44.0%) |
| OE | 2 (8.3%) | 3 (12.0%) |
| UE | 2 (8.3%) | 2 (8.0%) |
Blood pressure and blood glucose were tested prior to the administration of rt‐PA.
RIC, remote ischemic conditioning; OTT, onset‐to‐treatment time; NIHSS, National Institute of Health Stroke Scale; TIA, transient ischemic attack; CHD, coronary artery heart disease; CISS, China ischemic stroke subclassification; LAA, large artery atherosclerosis; CS, cardiogenic stroke; PAD, penetrating artery disease; OE, other etiology; UE, undetermined etiology.